Inogen (NASDAQ:INGN) Raised to Hold at StockNews.com

StockNews.com upgraded shares of Inogen (NASDAQ:INGN) from a sell rating to a hold rating in a research note published on Saturday.

Several other analysts have also commented on the company. Needham & Company LLC reiterated a hold rating on shares of Inogen in a report on Wednesday, May 8th. Stifel Nicolaus increased their price objective on Inogen from $6.00 to $7.00 and gave the company a hold rating in a report on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of Hold and an average target price of $7.00.

Inogen Stock Down 3.2 %

Shares of NASDAQ:INGN opened at $9.36 on Friday. Inogen has a 52-week low of $4.13 and a 52-week high of $10.64. The stock has a market cap of $220.71 million, a P/E ratio of -2.26 and a beta of 1.07. The business’s 50 day moving average is $8.49 and its 200 day moving average is $7.75.

Inogen (NASDAQ:INGN) last posted its earnings results on Tuesday, May 7th. The medical technology company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.14. The company had revenue of $78.03 million during the quarter, compared to analyst estimates of $73.67 million. Inogen had a negative return on equity of 42.87% and a negative net margin of 30.07%. Inogen’s revenue was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.63) earnings per share. On average, sell-side analysts anticipate that Inogen will post -2.2 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Jason Somer sold 10,000 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $8.56, for a total transaction of $85,600.00. Following the sale, the executive vice president now directly owns 4,452 shares in the company, valued at approximately $38,109.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.99% of the stock is owned by insiders.

Institutional Investors Weigh In On Inogen

Institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its stake in Inogen by 84.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,288 shares of the medical technology company’s stock valued at $29,000 after buying an additional 2,419 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of Inogen by 2,918.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,908 shares of the medical technology company’s stock valued at $43,000 after buying an additional 7,646 shares during the period. CWM LLC raised its position in shares of Inogen by 2,185.9% during the 2nd quarter. CWM LLC now owns 6,629 shares of the medical technology company’s stock valued at $54,000 after buying an additional 6,339 shares during the period. SG Americas Securities LLC raised its position in shares of Inogen by 27.8% during the 4th quarter. SG Americas Securities LLC now owns 12,782 shares of the medical technology company’s stock valued at $70,000 after buying an additional 2,782 shares during the period. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Inogen during the 1st quarter valued at approximately $81,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.